Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one of the following: * Acute lymphocytic leukemia (ALL): * Complete remission (CR) 1 - high risk defined as overt CNS involvement or poor cytogenetics (additions, deletions, translocations, or multiple abnormalities) * CR2 * Induction failures * Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt * Acute myelogenous leukemia (AML): * CR1 - high risk defined as poor cytogenetics (deletions, additions, multiple abnormalities) * CR2 * Induction failures * Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt * Chronic myelogenous leukemia (CML): * Chronic phase (CP) 1 * Accelerated phase/CP2 - patients in blast phase must undergo treatment and achieve a second chronic phase prior to transplant * Chronic lymphocytic leukemia (CLL): * Relapse - any stage; must have received no more than 3 prior regimens * Multiple myeloma: * At diagnosis - primary refractory * Relapse (no more than 2) - sensitive disease * Plasma cell leukemia * Inability to achieve a complete remission after autologous transplant (no older than 40) * Myelodysplasia - all subtypes * Myeloproliferative disorders - patients with poor response to medical therapy or cytogenetic abnormalities * Severe aplastic anemia (SAA): * Very SAA - at diagnosis * SAA - induction therapy * Donors mus…